29-07-2021, 04:00 PM
https://www.infectioncontroltoday.com/vi...o-vaccines
July 27, 2021
Frank Diamond
nvestigators in Chile conclude that the lambda COVID-19 variant is not only more infectious than standard SARS-CoV-2, but could also possibly shrug off vaccines. The first case in the United States has been spotted at Houston Methodist Hospital.
A COVID-19 variant that proves to be resistant to vaccines keeps medical experts, public health officials, and health care professionals—including infection preventionists—on the frontlines of the COVID-19 pandemic up at nights. There’s no reason to sound the alarm yet, but there may—just may—perhaps be reason to think that there’s a chance that the alarm may have to be sounded at some point about the lambda COVID-19 mutation, or C.37.
A preprint study by investigators in Chile suggests that the mutation, which first surfaced in Peru about a year ago and is highly infectious, may also be able to evade vaccine antibodies.
“Our results indicate that mutations present in the spike protein of the lambda variant of interest confer increased infectivity and immune escape from neutralizing antibodies elicited by CoronaVac,” the study states. CoronaVac is a vaccine manufactured by a Chinese company and that’s used in Peru. The study continues: “These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough.”
July 27, 2021
Frank Diamond
nvestigators in Chile conclude that the lambda COVID-19 variant is not only more infectious than standard SARS-CoV-2, but could also possibly shrug off vaccines. The first case in the United States has been spotted at Houston Methodist Hospital.
A COVID-19 variant that proves to be resistant to vaccines keeps medical experts, public health officials, and health care professionals—including infection preventionists—on the frontlines of the COVID-19 pandemic up at nights. There’s no reason to sound the alarm yet, but there may—just may—perhaps be reason to think that there’s a chance that the alarm may have to be sounded at some point about the lambda COVID-19 mutation, or C.37.
A preprint study by investigators in Chile suggests that the mutation, which first surfaced in Peru about a year ago and is highly infectious, may also be able to evade vaccine antibodies.
“Our results indicate that mutations present in the spike protein of the lambda variant of interest confer increased infectivity and immune escape from neutralizing antibodies elicited by CoronaVac,” the study states. CoronaVac is a vaccine manufactured by a Chinese company and that’s used in Peru. The study continues: “These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough.”
